Many patients with RA, AS and PsA experience restrictions in participating in the labour force. This reduces quality of life but also affects social insertion and economic autonomy of a patient. During the past decade, treatment strategies have been intensified and, additionally, a number of biologic therapies have been introduced for the treatment of these diseases. Treatment with biologic therapies has proved to be clinically effective and retard radiographic damage. Although less frequently investigated, a number of studies also determined the impact of biologic therapy on employment. However, the results in these studies are conflicting, which may partly be explained by the variation in methods used to assess the association between biologic therapy and employment/productivity loss. The aim of this overview is to critically appraise the different methodological approaches used in studies that evaluated the effect of biologic therapies on employment/productivity loss outcomes in inflammatory arthritis. The specific aims are to compare and discuss: (i) differences in population characteristics and study design including the use of a control group; and (ii) differences in methods used to assess and quantify productivity loss.
Introduction
In the past decade, a number of biologic therapies have become available for use in the treatment of RA, AS and PsA. In all three patient populations, treatment with these biologic therapies has proved to be clinically effective [17] . A number of studies, especially in RA, have also investigated the effect of biologic therapies on (changes) in employment. Employment is a relevant outcome from a patient's perspective and from a societal perspective. To date, results between studies investigating the effect of biologic therapies on employment/productivity loss are difficult to interpret and seem conflicting. This may partly be explained by differences in population characteristics between the studies (e.g. level of disease activity, early disease vs established disease), study design (clinical trials or observational studies) including duration of follow-up and differences in outcome measures used to define (change in) employment status, days absent from work or at-work productivity loss. The aim of this literature overview was to explore and discuss the variation in methods used in published literature assessing employment/productivity loss in patients with inflammatory rheumatic diseases treated with biologic DMARDs.
Methods of selecting published papers
PubMed, MEDLINE and Cochrane databases were searched for manuscripts investigating the effect of biologic therapies on employment/productivity loss in patients with inflammatory arthritis treated with biologic therapies (publication date before 31 March 2011).
The following search terms were used: biological OR anti TNF OR TNF inhibitor OR etanercept OR infliximab OR adalimumab OR anakinra OR abatacept OR golimumab OR rituximab OR certolizumab OR tocilizumab OR anti tumor necrosis factor; and employment OR work OR work disability OR disability OR sick leave OR productivity OR employability OR work ability OR absenteeism OR presenteeism OR sick absence OR work instability OR return to work OR economic consequence OR occupational health. All searches were performed for the following three patient populations: RA, AS and PsA. Only full manuscripts were included in this review because abstracts may not provide enough data on methods used to measure productivity loss. It should be emphasized that the aim of this review was not to conduct a systematic review but to explore and discuss the variation in methods used in published literature assessing employment/productivity loss in patients with inflammatory rheumatic diseases treated with biologic DMARDs. The main criterion for including a study was that original data should be reported. There were no limitations with respect to study design, type of work and quality of the study. Studies were not included if they included the same study population of one of the already selected papers [8, 9] or when it was not possible to extract data specifically related to the biologic therapy group [10] .
Data extraction comprised two main themes. First, data on study design, population selection, country and demographic characteristics were extracted from all manuscripts to give an overview of the study population and study design in general. Secondly, to compare the approaches and measures used to assess their impact on the main paid productivity outcomes. Throughout the manuscript we will briefly summarize the results of all studies to substantiate the impact of methods used on the results.
Description of study population and study design
Study population
Of the 31 studies identified, 20 concerned RA [9, 1129], 7 AS [7, 3035] , 3 PsA [3638] and 1 study included all three patient populations [39] (Table 1) . Of the studies, 4 were carried out in the UK [18, 31, 34, 39] , 5 in the USA [17, 26, 27, 37, 38] , 2 in the Netherlands [9, 19] , 4 in Sweden [2325, 29] , 2 in Canada [20, 28] , 1 in USA/Canada [36] , 2 in Germany [7, 32] , 1 in Australia [35] and 10 were international collaborations [1116, 21, 22, 30, 33] . In the latter studies, country-specific data of participating countries were not reported. Most studies reported from databases or studies that were not primarily designed to investigate the effect of biologic therapy on employment/productivity loss. The sample sizes ranged from 20 [31] to 3291 patients [39] when all patients included were considered and from 20 [31] to 1986 [26] gainfully employed patients at baseline. In only one study, the sample size was based on job loss [18] . It is therefore likely that some studies were underpowered to adequately address work productivity outcomes and to reliably reflect the diversity of the labour market with regards to job content (quality and quantity of performed work), contextual factors (transportation, work adaptability, potential help from professional environment). All these elements may have substantial impact on work participation and are likely to prevent the detection of any changes in employment status.
Early vs established disease
As for several other outcomes, disease duration will be an important characteristic of the population when employment status (i.e. in paid employment or not working due to health) is the outcome. Previous studies have shown that severe joint damage is associated with irreversible disability and the inability to improve this disability declines with disease duration [40] . Even if patients with long-standing RA who have become work disabled respond to biologic therapies, the likelihood of regaining employment is very low [41, 42] . In early RA, on the other hand, there is an important opportunity to prevent work disability. Five studies included patients with a mean/median disease duration of <1 year [1215, 18] . In all other studies mean/median disease duration was longer than $5 years [7, 9, 11, 16, 17, 1939] . A protective effect of anti-TNF on employment was more often seen in patient populations with an average disease duration of <1 year compared with patients with long-standing disease who were more likely to be already out of the labour market (Table 2 ). This effect is also illustrated by the study of Allaire et al. [27] , who did not find an association between anti-TNF and employment in the total study population, but a protective effect was found for users with a disease duration of <11 years. In contrast, anti-TNF treatment was a predictor for work disability in patients with a disease duration of >11 years since such treatments are given to the more severely affected patients.
Study design
It is well-known that while randomized clinical trials (RCTs) have high internal validity, their generazability is limited. Moreover, the follow-up duration is typically short (often <1 year). While this might be appropriate for sick leave in those employed or in those having problems at work/productivity loss, it will likely be a problem when employment status is the outcome since actual changes in work status often occur later in the disease. Observational studies, on the other hand, have usually better generalizability and patients are followed for a longer period of time but are often not designed to collect detailed data on productivity loss. Moreover, the impact of biologic therapies on work outcomes is limited by the lack of standardized and homogeneous therapeutic strategies as well as the lack of a comparator group based on randomization. Finally, interpretation of long-term data should preferably be done by taking into account the economic environment and secular trends in absence from work or work disability.
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[23], the percentages of patients on sick leave or disability pension were compared with rates of the general population. By using the general population as comparison group, it is not possible to estimate the true effect of biologic therapies compared with conventional therapies, except by comparing pre-and post-biologic periods. However, this study allows especially to adjust for trends in days absent from work or employment changes and for trends in the general population reflecting general labour market changes, an important issue not covered by any of the other studies. It should also be noted that the study by Olofsson et al.
[23] was focused on completers and was not based on intentionto-treat analysis.
Measures of employment and productivity loss

Employment status
Employment is a broad concept and refers to the role individuals have in society and comprises (full or partial) paid employment, being economically unemployed and work disability. In clinical studies, employment is measured as whether or not an individual is in a state of paid employment or not (due to health) at the point of assessment. As previously observed in a review including studies of the pre-biologic era [43] , employment status and reasons for not being employed were also not assessed uniformly across studies conducted in populations receiving biologic therapies and reviewed in this paper, and thus limiting comparability (Table 3) 
Employability
In recent years, employability has been introduced as an employment outcome measure and can be applied to those working and currently not working due to health. It includes a subjective evaluation of the individual whether or not he/she feels able to work. This would adjust for the fact that persons who were not employed but felt better due to therapy were not able to find work (e.g. because no job is available). On the one hand, the WAI and VBBA Baseline and 6 months WAI: rating of current work ability using the lifetime best work ability as the reference Current NA VBBA: assessing the (changes) in work characteristics in patients with paid work. Each subscale has 9 to 11 items scored on a four-point scale (0 = never to 3 = always). The final score is transformed to a scale ranging from 0 to 100 (higher score reflects worse psychological work characteristics)
NFR: fatigue questionnaire measuring the need to recover after work Answers are measured on an 11-point Likert scale and transformed to scale scores (0 to 100 = more work-related fatigue) (continued) Herenius et al.
[9] WAI questionnaire; NFR questionnaire; and VBBA questionnaire Baseline, 6 and 12 months VAS work ability (0 = very low perceived work ability to 10 = best self-perceived work ability) Current Arthritis NFR: fatigue questionnaire measuring the need to recover after work. Answers are measured on a 11-point Likert scale and transformed to scale scores (from 0 to 100 = more work-related fatigue) VBBA: assessing the (changes) in work characteristics in patients with paid work. Each subscale has 9 to 11 items scored on a four-point scale (0 = never to 3 = always). The final score is transformed to a scale ranging from 0 to 100 (higher score reflects worse psychological work)
Wolfe et al.
[ In patients who were not employed, patients were asked if they could work if a job became available (employability) VAS productivity (0 = daily productivity affected very much to 10 = daily productivity not affected at all)
Kimball et al. measure has no instant economic consequences. On the other hand, the outcome is very appealing because it is a relevant outcome for the patient and might be a good predictor for actual employment status in the long term [44] . Whether patients who indicate that they are able to work if a job becomes available indeed start to work is also dependent on other factors including contextual factors (e.g. unemployment rate in country, possibilities to adapt future working environment, working flexible hours, personal circumstances at home, etc.), changes in labour market and disease activity at the time a job actually becomes available. A positive association between biologic therapy and increased employability was found in one RA study [14] but not in the PsA study [38] .
Absence from paid work
Absence from paid work has been defined as productivity loss due to (health-related) absence. Absenteeism includes days off sick, short-term or long-term sick leave and personal time of work. Eight studies [12, 14, 15, 20, 28, 30, 37, 38] measured the number of missed working days. Interestingly, only a few studies reported the number of hours a patient worked [9, 17, 19, 21, 29, 31] at baseline. This could be important when converting estimated number of days missed from work or time on sick leave into absenteeism-related costs or when expressing percentage lost productivity time.
At-work productivity loss
At-work productivity loss refers to reduced performance or productivity due to health while at work and is also referred to as presenteeism. Different approaches exist to assess at-work productivity loss/limitations, exploring different aspects of productivity such as job performance, quantity or quality of work, work efficiency, the degree of difficulty to perform their work [45] . A number of tools, including various validated questionnaires, were used to measure at-work productivity loss and they differed importantly in the extent of limitations and productivity loss they assessed. In six studies that studied at-work productivity loss, the following validated questionnaires were used: the Health and Labour Questionnaire (HLQ) [20] 31, 46] . Although content validity and reliability of most of these measures are relatively good, correlations between different instruments are low to moderate [47, 48] ; a possible indication of different concepts, recall, disease attribution or reference framing. In the study by Anis et al.
[12], at-work productivity loss estimates were derived from mapping WPAI and Work Limitation Questionnaire (WLQ) scores based on HAQ scores. The estimates varied widely according to the instrument, and such mapping exercises need to be more extensively evaluated. Other studies used a visual analogue scales (VAS) based on different concepts, such as work performance [15] , daily productivity [30, 38] and ability to work [34] , to measure at-work productivity loss. The VAS is a simple tool to apply in clinical studies, but converting perceived reductions in performance/efficiency into monetary terms is challenging.
Other outcomes
In two Dutch studies [9, 19] a broader perspective was taken into account, including questions on work characteristics, work satisfaction and psychosocial work characteristics. In these two studies, the need for recovery from fatigue after work was also measured. In two studies, The Short Form (36) Health Survey (SF-36) was used to assess work outcomes [13, 16] .
Main methodological issues and confounding
Recall period
One of the methodological issues arising from measuring days missed from work, sick leave and at-work productivity loss is the recall period used in questionnaires. In the studies shown in Table 3 , the recall period ranged from 2 weeks to 1 year. A short recall period of 4 weeks is probably less likely subject to recall bias when compared with a recall period of >6 months in studies evaluating days missed from work or sick leave [49] . When the recall period is too short, one might miss variability in sick leave or presenteeism over time. For example, when extrapolating the number of missed days from work recorded over a 4-week period to a period of 1 year, under-or overestimation of days off work due to health may occur at an individual level as most patients with arthritis experience periods in which their disease is under control followed by episodes of disease flare and increased functional disability [50] . To actually measure changes in days missed from work and at-work productivity loss over time in individual patients, taken into account fluctuations in disease activity, the use of weekly diaries, a method used by Bejarano et al. [18] for sick leave, is probably desirable but may not always be feasible or could expose to substantial missing data. These issues also arise when patients are asked whether they are on sick leave and record the time on sick leave since last contacted. If patients are on long-term sick leave, start and end dates of sick leave should preferably be recorded. The recall bias specific to self-reported data may be avoided for sick leave by using insurance or payer medico-administrative data when available.
Attribution
Measures for employment, sick leave or presenteeism used in the reviewed studies were attributed to RA, AS or PsA (disease specific), attributed to overall health problems (generic) or the attribution was not mentioned. As an example for measuring number of days/hours missed at work the attribution was disease specific in nine studies [4, 7, 11, 14, 15, 20, 28, 30, 33, 37] and generic in one study [12] . Which attribution is used may have an impact on the actual results and makes comparison between studies difficult. Generic measures have the advantage that they can be used to compare the impact www.rheumatology.oxfordjournals.org of health on work outcomes across different diseases and even in the general population. However, if one wants to evaluate the effect of therapy on paid productivity in patients with arthritis, a disease-specific instrument may be more appropriate to get better accuracy and sensitivity to change. In two studies, both disease specific and generic assessments were performed. In the casecontrol study by Allaire et al. [27] , looking at the anti-TNF as a predictor for work disability, similar results were found for work disability in general and RA-attributed work disability. Also in another study, no difference was observed between the percentage of patients with job loss due to any cause or job loss attributable to RA [18] .
Confounding
For both RCTs and observational studies adjustment for confounding should be considered. RCTs are less susceptible to confounding due to selection between the active treatment group and comparison group. Notwithstanding, it was remarkable that none of the RCTs compared the success of randomization with regard to educational level, job type, employment status or hours worked. Observational studies are more prone to confounding due to selection bias in the comparison group than RCTs [51] . Control patients receiving conventional DMARDs often have less disease activity, shorter disease duration and possible comorbidities precluding prescription of biologic therapies. By adjusting for confounders or using stratification, confounding can be reduced. Some residual confounding will, however, remain because of unknown confounders or known confounders for which data have not been collected. The latter is especially a problem since the focus of most observational studies and biologics registries is looking at short-term and long-term treatment effects/ adverse events, such as disease activity and adverse events, and not evaluating (change in) employment. In the study by Farahani et al. [28] it is not clear which variables were included in the Analysis of Covariance. Except for one study [39] , most observational studies in which a comparison group was included, data were only adjusted for baseline disease-related confounders and not job-specific confounders. In another study [17] comparing data from patients who participated in RCTs with data from patients participating in an observational study, covariates also included level of education and indicator variables for occupation and industries. There is no consensus on the list of confounders that should be included, especially with regards to contextual factors. In three studies, no significant difference in missed days from work [28] , work disability rates [39] and social security disability [26] between the biologic therapy group and the comparison group were observed. In the study by Halpern et al. [22] , patients receiving adalimumab were less likely to stop working, whereas in the study by Wolfe et al.
[26] patients receiving anti-TNF therapy were at increased risk for self-reported disability. In the latter study, both crude and adjusted odds ratios (ORs) were reported, showing more attenuated ORs in a full model adjusting for all possible confounding variables compared with the model with crude and the model including only demographic and comorbidity covariates.
Discussion
Measuring productivity loss seems challenging given the impact of chosen study design, population, inclusion of a comparison group, definition of employment outcome measure, recall period and attribution on the final outcome. Depending on the type of outcome, studies have different needs. First, clinical trials often are of a short duration ranging from 1 to a maximum of 2 years in which actual employment changes, especially gain in employment, is less likely to occur, whereas changes in sick leave and at-work productivity loss are more likely to be seen earlier. We, therefore, recommend to include at least measures of sick leave and at-work productivity loss in studies of short duration. Secondly, to investigate the additional effect of biologic therapy compared with conventional treatment a control group is mandatory and, especially in observational studies, outcomes should be adjusted for possible confounders. Thirdly, to be able to convert loss in productivity into monetary terms, number of contractual working days/hours should be recorded at each time point. This is also important since a reduction in number of working days/hours may also be associated with an increase of at-work productivity.
Although complex to address, other issues could also be included in studies or trials, such as contextual factors. Surprisingly, most studies did not evaluate the impact of contextual factors. The vast majority of studies included only demographic and disease characteristics as covariates in the analyses aiming to explore the impact of biologic therapies on productivity loss, except in two Dutch studies in which work characteristics, work satisfaction and psychosocial work characteristics were also evaluated [9, 19] . Contextual factors related to job or work characteristics and to the organization are highly important to understand work participation. The World Health Organization proposed to use the bio-psycho-social model to adequately address the impact of chronic conditions on work in terms of disability and productivity loss [52] . In this model, the biomedical part, i.e., disease characteristics and consequences on functional abilities, is complemented by the psycho-social part, which is represented by two components: first, personal factors such educational level, helplessness, coping, beliefs about health and work and job satisfaction; and secondly, the environmental factors such as job type, social support, sick leave compensation or disability pension, possibility of job adaptation, flexibility in working hours, feasibility of home-based work, adaptation of the work place or potential help from colleagues if some tasks are difficult to perform. All these factors may have substantial impact on the persistence of a sick worker on the market place. For example, a lower level of education has often been found as a negative predisposing factor for job loss. On the other hand, high responsibility jobs may result in premature discharge as short-term sick leave or loss of productivity at work will not be easily accepted. In addition, the financial component can influence the decision to keep working. This factor is a sum of different aspects: daily wage, family wage and amount of retribution from the health insurance that may be widely different between countries [53] . Although these contextual factors are numerous and may greatly vary across occupations and workers, they are accessible through validated questionnaires such as the job content questionnaire based on the effortdemand model [54] or the effortreward imbalance questionnaire based on the eponym model [55] . Such tools enable better explanation of productivity loss; however, they are rarely used in RCT or observational studies that have been conducted in the field of inflammatory arthritis. Their incorporation in future studies exploring the impact of biologic agents on work productivity is thus advisable.
We have shown that there is a wide variety in methods used to measure changes in paid productivity loss and that this may explain the conflicting results in studies looking at the effect of biologic therapies on paid productivity. For future studies, consensus should be on reached how to measure productivity loss in patients with arthritis.
Rheumatology key messages
. Methods to measure productivity loss in patients receiving biologic therapies vary widely across studies. . Consensus should be reached on how to measure productivity loss in future clinical trials and observational studies. 
